Navigation Links
WuXi PharmaTech Announces Third-Quarter 2013 Results
Date:11/12/2013

employee stock option and restricted stock programs.

Full-Year 2013 Financial GuidanceWuXi PharmaTech updates its full-year 2013 financial guidance as follows:

  • Total net revenues of $574-578 million, or 15-16% year-over-year growth, compared to previous guidance of $572-578 million
  • GAAP and non-GAAP gross margin and operating margin comparable to those in 2012, the same as previous guidance
  • GAAP diluted earnings per ADS of $1.51-$1.55, compared to previous guidance of $1.38-$1.44
  • Non-GAAP diluted earnings per ADS of $1.73-$1.77, compared to previous guidance of $1.61-$1.67
  • Capital expenditures of about $60 million, the same as previous guidance
  • Fourth-Quarter 2013 Financial GuidanceWuXi PharmaTech provides the following fourth-quarter 2013 financial guidance:

  • Total net revenues of $153-157 million, or 22-25% year-over-year growth
  • GAAP diluted earnings per ADS of $0.38-$0.42
  • Non-GAAP diluted earnings per ADS of $0.44-$0.48
  • WUXI PHARMATECH (CAYMAN) INC.UNAUDITED CONSOLIDATED BALANCE SHEETS(in thousands of U.S. dollars, except ordinary share, ADS and par value data)September 30,
    2013December 31,
    2012Assets:Current assets:Cash and cash equivalents145,161

    54,133Restricted cash3,506

    423Short-term investments180,867

    175,245Accounts receivable, net119,384

    99,578Inventories41,074

    47,774Prepaid expenses and other current assets34,341

    18,807Total current assets524,333

    395,960Non-current assets:Goodwill31,085

    32,561Property, plant and equipment, net264,363

    264,381Long-term investments23,979

    14,015Intangible assets, net6,233

    7,268Land use rights5,591

    5,564Deferred tax assets2,545

    3,037Other non-current assets4,946

    19,749Total non-current assets338,742

    346,575Total assets863,075

    742,535Liabilities and equity:Curr
    '/>"/>

    SOURCE WuXi PharmaTech
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinics Center for Individualized Medicine
    2. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
    3. WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release
    4. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
    5. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
    6. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
    7. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
    8. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
    9. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
    10. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
    11. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... PRINCETON, N.J. , Dec. 24, 2014 /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today that on ... registered public offering. The Company raised ... offering and intends to use the net proceeds ...
    (Date:12/24/2014)... 24, 2014  Diplomat Pharmacy, Inc. (NYSE: ... proud to announce Jennifer Hagerman , Pharm.D., AE-C, ... take office as the president of the Michigan Pharmacists ... will take place Feb. 28, 2015, at the MPA ... the Renaissance Center in Detroit, Michigan ...
    (Date:12/24/2014)... SCHOFIELD, Wis. , Dec. 23, 2014 ... and marketer of over-the-counter (OTC) medicinal and healthcare products, ... production of MigraPure® H, a hemp-based, advanced headache relief ... marijuana dispensaries in Colorado , ... . With the MigraPure H Advanced ...
    Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
    ... Tolerability and,Additive Antiviral Activity of HCV-796 -, EXTON, ... announced additional data from a Phase 1b study,of ... virus (HCV),polymerase inhibitor at the 42nd Annual Meeting ... Liver (EASL). This meeting is,being held in Barcelona, ...
    ... Data on Innovative Oncology Compounds at the,American ... PARK, Ill., April 13, 2007 /PRNewswire-FirstCall/ -- ... that target,cancer. Researchers now know that cancer ... new blood vessels to deliver oxygen,and nutrients ...
    Cached Medicine Technology:ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 2ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 3ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 4ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 5ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 6Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 2Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 3Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 4
    (Date:12/24/2014)... York, New York (PRWEB) December 24, 2014 ... ( http://www.xareltolawsuit2015.com/ ) that allege the blood thinner ... complications has outlined a leadership structure for the ... Order dated December 17th, the Court plans to ... the parties and also plans on appointing a ...
    (Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... drug which is used in the treatment of colon ... is also prescribed to patients who suffer from advanced ... is a multi-kinase inhibitor and it blocks many enzymes ...
    (Date:12/24/2014)... By Dennis Thompson HealthDay ... and bisexual men who have abstained from sex for one year ... a new federal policy that would reverse a 31-year ban on ... Food and Drug Administration announced Tuesday its intention to release a ... door to blood donations from gay men. The FDA is ...
    (Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- A new, ... Food and Drug Administration. The agency on Tuesday ... for those who are overweight and have at least ... type 2 diabetes or high cholesterol. Patients taking ... a low-calorie diet and exercise regularly, the FDA noted. ...
    (Date:12/24/2014)... Tara Haelle HealthDay ... -- Teens are more likely to start smoking or ... hyperactivity disorder (ADHD) or conduct disorder, new research ... families about the risk of substance use as [these] ... research director at Cincinnati Pediatric Research Group, which is ...
    Breaking Medicine News(10 mins):Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3
    ... Ann Karmanos Cancer Institute and Karmanos Cancer Center ... Ann G. Schwartz, Ph.D. has been appointed Interim ... has been appointed Interim Chief Operating Officer.(Logo: ... to lead us during this period of transition," ...
    ... 5 Change to Win chair Anna ... House Forum on Health Reform, which was attended by various ... as a nation that are as complex and consequential as ... their health coverage every day, we can no longer turn ...
    ... The Pennsylvania Breast Cancer Coalition and the Pennsylvania Association of ... sign up for the 2nd annual Home Run Derby EPHRATA, ... out your baseball bat and head out to the ballpark! ... of Community Bankers have joined together once again to bring ...
    ... International, LLC officially kicks off "Sleep Better America," ... campaign, with the launch of http://www.sleepbetteramerica.net . ... consumers about sleep-related issues with timely information, tools, ... studies.The "Sleep Better America" Web site centralizes unique ...
    ... The medication patches should be removed ahead of time, ... The U.S. Food and Drug Administration warned Thursday that ... while patients undergo an MRI. , Thursday,s warning applies ... over-the-counter -- including nicotine and pain-control patches. , Some ...
    ... suggests that the standard treatment for a common brain ... leaving patients more vulnerable to tumor recurrence. The research, ... of the journal Cell Stem Cell , provides ... stem-like cells to escape cytotoxic treatment and repopulate the ...
    Cached Medicine News:Health News:Karmanos Cancer Institute Announces Interim Leadership 2Health News:Karmanos Cancer Institute Announces Interim Leadership 3Health News:Change to Win Statement on White House Health Care Forum 2Health News:Take A Swing Against Breast Cancer! 2Health News:AmericInn Hotels Kicks-Off 'Sleep Better America' With Launch of New Web Site to Educate Consumers About Insomnia and Sleep-Related Issues 2Health News:Skin Patches Can Cause Burns During MRIs 2Health News:Brain tumor treatment may increase number of cancer stem-like cells 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: